- Home
- ASC vs DRTS Comparison
ASC vs DRTS Comparison
Compare ASC & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASC | DRTS |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | Bermuda | Israel |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 508.7M | 607.1M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASC | DRTS |
|---|---|---|
| Price | $16.40 | $7.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $15.00 | $9.50 |
| AVG Volume (30 Days) | ★ 692.0K | 310.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $30.44 | N/A |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.32 | $2.30 |
| 52 Week High | $16.00 | $8.60 |
Technical Indicators
Market Signals| Indicator | ASC | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 83.55 | 55.21 |
| Support Level | $9.37 | $6.57 |
| Resistance Level | N/A | $7.77 |
| Average True Range (ATR) | 0.48 | 0.49 |
| MACD | 0.21 | -0.00 |
| Stochastic Oscillator | 99.14 | 42.94 |
Price Performance
Historical ComparisonAbout ASC Ardmore Shipping Corporation
Ardmore Shipping Corp provides seaborne transportation of petroleum products and chemicals world-wide to oil majors, national oil companies, oil and chemical traders, and chemical companies, with its modern, fuel-efficient fleet of mid-size product and chemical tankers. The Company operates its business in one operating segment, the transportation of refined petroleum products and chemicals.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.